PK MED

PK MED is a French biotechnology company founded by Truffle Capital in 2019, dedicated to developing injectable smart implants for drug delivery in rheumatology and cell homing in bone marrow transplants. PK MED’s unique expertise and technical knowledge enable the transformation of existing systemic treatments into new, safer, and more effective patented local therapies. PK MED has developed a series of projects targeting indications with high medical needs, starting with gout (PKM-01) and hematopoietic stem cell transplantation (PKM-02).